1
|
Viswanatha GL, Rafiq M, Thippeswamy AHM, Yuvaraj HC, Kavya KJ, Baig MR, Suryakanth DA, Azeemuddin M, Patki PS, Pushpalatha HB, Chaudhari PS, Shyam R. Ameliorative effect of Koflet formulations against pyridine-induced pharyngitis in rats. Toxicol Rep 2014; 1:293-299. [PMID: 28962246 PMCID: PMC5598515 DOI: 10.1016/j.toxrep.2014.05.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Revised: 04/21/2014] [Accepted: 05/08/2014] [Indexed: 11/30/2022] Open
Abstract
In present study two formulations of Koflet (syrup and lozenges) were evaluated against pyridine-induced pharyngitis in rats. Topical application of 10% pyridine showed extravasation of Evans blue stain as a characteristic feature of on-going inflammation. In addition, the levels of TNF-α (p < 0.01) and IL-6 (p < 0.01) were significantly increased compared to control. Further, histopathology of the pharyngeal tissue showed submucosal gland hypertrophy, severe mucosal inflammation characterized by presence of mononuclear cells and neutrophils along with haemorrhages and congestion; however, saline applied animals (normal control) showed normal cytoarchitecture of the pharynx. Interestingly, pre-treatment with dexamethasone (1 mg/kg, p.o.), Koflet lozenges (KL) (500 and 1000 mg/kg, p.o.) and Koflet syrup (KS) (2 and 4 ml/kg, p.o.) for 7 days showed significant and dose dependent protection by decreasing the EB dye extravasation, and serum levels of TNF-α and IL-6. In addition, histopathological findings have further supported the protective effect of Koflet formulations. These findings suggest that, both Koflet syrup and Koflet lozenges are highly effective in treating non-infectious type of pharyngitis. Among the two formulations KS was found to be more potent than KL, and possible mechanism of action thought to be mediating through inhibition of TNF-α and/or phospholipids–arachidonic acid pathway.
Collapse
Affiliation(s)
- G L Viswanatha
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - Mohamed Rafiq
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - A H M Thippeswamy
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - H C Yuvaraj
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - K J Kavya
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - Mirza Rizwan Baig
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - D A Suryakanth
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - Mohammed Azeemuddin
- Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - P S Patki
- Head-Medical Services & Clinical Trials, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - H B Pushpalatha
- Formulation & Development, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - Prafulla S Chaudhari
- Formulation & Development, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| | - Ramakrishnan Shyam
- Chief Scientific Officer, R&D Center, The Himalaya Drug Company, Bangalore 562 162, India
| |
Collapse
|